Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	54.57B +43.3%
Revenue (ttm)	16.57B +14.7%
Net Income	1.93B -9.4%
EPS	1.08 -10.0%
Shares Out	n/a
PE Ratio	28.35
Forward PE	21.20
Dividend	0.22 (1.08%)
Ex-Dividend Date	Jul 4, 2025

Volume	4,599,079
Average Volume	5,665,861
Open	19.20
Previous Close	19.64
Day's Range	18.94 - 19.60
52-Week Range	12.88 - 30.12
Beta	0.83
RSI	40.82
Earnings Date	Apr 29, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial numbers in CNY